Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer

  • Authors:
    • Peng Zhang
    • Hui Wang
    • Jianming Wang
    • Qingzuo Liu
    • Yongqiang Wang
    • Fan Feng
    • Lei Shi
  • View Affiliations

  • Published online on: May 31, 2017     https://doi.org/10.3892/ol.2017.6282
  • Pages: 1657-1664
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Promoter hypermethylation of tumor suppressor genes has been confirmed to serve a pivotal role in tumorigenesis. Protocadherin 8 (PCDH8), a novel tumor suppressor gene, has been reported to be inactivated by promoter hypermethylation a number of cancer types, including bladder cancer and renal cell carcinoma. The aim of the present study was to investigate the occurrence of PCDH8 hypermethylation in prostate cancer and its potential as a novel biomarker of prostate cancer. The transcriptional levels of PCDH8 were examined by quantitative polymerase chain reaction (PCR) in 82 prostate cancer tissues as well as 30 prostate hyperplasia tissues, and verified the protein level by western blot analysis of representative samples. PCDH8 expression levels were found to be reduced to 0.30±0.10 in 70.7% (58/82) of prostate cancer tissues. To identify the possible reason for mRNA downregulation, the methylation status of the PCDH8 promoter was assessed in prostate cancer tissues and prostate hyperplasia tissues by methylation‑specific PCR (MSP). A total of 47 prostate cancer patients who exhibited reduced PCDH8 expression (57.3%; 47/82) also showed promoter hypermethylation (47/58). None of the samples (0/30) in the benign prostate hyperplasia group were positive on MSP. Furthermore, the associations between the methylation status of the PCDH8 promoter and various clinicopathological features of prostate cancer were analyzed, revealing that the methylation status of PCDH8 was closely associated with tumor size, tumor shape (papillary/non-papillary), tumor stage and tumor grade (all P<0.05), while there were no correlations with the age of the patients or the number of tumors (P>0.05). Additionally, patients with hypermethylation of the PCDH8 gene promoter had a relapse rate of 36.17% and a mortality rate of 29.79%, which were significantly higher than the hypermethylation-negative patients (P<0.05), indicating a poorer prognosis. Therefore, the methylation status of the PCDH8 gene in prostate cancer may be an important marker for use in the early diagnosis and prediction of prognosis in prostate cancer.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang P, Wang H, Wang J, Liu Q, Wang Y, Feng F and Shi L: Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer. Oncol Lett 14: 1657-1664, 2017
APA
Zhang, P., Wang, H., Wang, J., Liu, Q., Wang, Y., Feng, F., & Shi, L. (2017). Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer. Oncology Letters, 14, 1657-1664. https://doi.org/10.3892/ol.2017.6282
MLA
Zhang, P., Wang, H., Wang, J., Liu, Q., Wang, Y., Feng, F., Shi, L."Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer". Oncology Letters 14.2 (2017): 1657-1664.
Chicago
Zhang, P., Wang, H., Wang, J., Liu, Q., Wang, Y., Feng, F., Shi, L."Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer". Oncology Letters 14, no. 2 (2017): 1657-1664. https://doi.org/10.3892/ol.2017.6282